Skip to content

VALIDATE: Virtual Agent Linked Intelligent Disease Assessment Tool Engine

VALIDATE: Virtual Agent Linked Intelligent Disease Assessment Tool Engine

Status
Withdrawn
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03153618
Acronym
VALIDATE
Enrollment
0
Registered
2017-05-15
Start date
2017-09-01
Completion date
2017-11-30
Last updated
2017-09-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Brief summary

The collection and analysis of family, medical, lifestyle, and environmental exposure history (a Comprehensive Health History or CHH) can identify critical risk factors for many chronic and life-threatening conditions, including cancer. Despite its importance, CHH is infrequently documented and analyzed in primary-care medical practice due to numerous hurdles, and currently available tools have proven inadequate to address this critical problem. This study will evaluate the Virtual Agent Linked Intelligent Disease Assessment Tool Engine (VALIDATE) system as an easy to administer, accurate, cost-effective, and clinically useful tool for collecting and analyzing structured CHH data.

Detailed description

Our study's objective is to evaluate the Virtual Agent Linked Intelligent Disease Assessment Tool Engine (VALIDATE) system as a means to improve the affordability and ease, while maintaining the validity and feasibility, of collecting, assessing, and acting on Comprehensive Health History data. Virtual Agents (VAs) are fully autonomous and embodied software agents that use both verbal (e.g. speech) and non-verbal modalities (e.g., gaze, gesturing) to simulate a clinician-patient encounter. These agents have already successfully shown advantages to patients for: entering family history data on their own, facilitating medication adherence, providing behavioral health information, serving as clinical interviewers, promoting breastfeeding, and educating about and motivating exercise and weight loss. The VALIDATE system has been developed to be a fully automated alternative to the currently extremely labor-intensive process of collecting and transcribing CHH data. VALIDATE will be evaluated for its capability to significantly diminish clinician time and cost to collect, review, analyze, and document accurate and complete certain CHH data directly from patients at home using their own personal desktop computers. VALIDATE will also be evaluated for its capability to identify valid clinical action, e.g. referral indications for familial cancer assessment based on American College of Medical Genetics and Genomics (ACMG)/National Society of Genetic Counselors (NSGC) and National Comprehensive Care Network (NCCN) Guidelines.

Interventions

OTHERVALIDATE system

Will be invited to interact with VALIDATE to answer questions about Family Cancer history and some personal medical and lifestyle history. Based on responses, VALIDATE will determine if they meet referral indications for cancer predisposition assessment.

Sponsors

Stanford University
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SCREENING
Masking
NONE

Intervention model description

In a two section clinic, the plan is to invite one section of newly enrolled patients coming to clinic for first visit to participate in interacting with VALIDATE while maintaining the standard of care within the other section for similarly matched patients. Parallel allocation design.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

All adults above the age of 18

Exclusion criteria

Children under the age of 18

Design outcomes

Primary

MeasureTime frameDescription
Percentage of participants satisfied with usage of VALIDATEUp to sixteen weeksAt the end of the session, participants will be asked if 1. they enjoyed the process d 2. if they prefer this process versus completing a web or paper form and 3. would they recommend the process to others?
Concordance of data collection - identified relativesUp to sixteen weeksAccuracy rates will be calculated by dividing the number of VALIDATE identified relatives by the number identified by a trained Clinician
Concordance of data collection - identified cancersUp to sixteen weeksAccuracy rates will be calculated by dividing the number of VALIDATE identified cancers by the number identified by a trained Clinician
Number of VALIDATE subjects versus Control subjects identified for further cancer predisposition assessment.Up to sixteen weeks

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026